Corcept Therapeutics Inc (CORT) reports increased revenue and expanding market opportunities, despite facing operational hurdles and ongoing litigation.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

Corcept attributed the revenue shortfall to supply chain issues at its specialty pharmacy vendor early in the quarter, which impacted its ability to fulfill a surge in demand. The company noted that ...

A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are ...

Discover insights from Corcept Therapeutics' Q1 2025 earnings call: revenue growth, relacorilant's FDA review, and its strategic outlook ...

A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a ...

INX-315 is an oral, investigational selective cyclin-dependent kinase 2 (CDK2) inhibitor. The designation was based on preclinical data as well as interim data from the ongoing phase 1/2 INX-315-01 ...

Biopharma company Corcept Therapeutics (NASDAQ:CORT) in Q1 CY2025, but sales rose 7.1% year on year to $157.2 million. On the ...

For the past 7 years, Bayer has shelled out billions of dollars in lawsuits brought by people claiming they developed cancer after exposure to its glyphosate-containing weed killers, including its ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...